NOVT
VENTE TOTALE: 663 titres (~97 858,80 $ US)
- Insiders
- Secor Thomas N
- Total bought
- —
- Total sold
- $97,859
- Last activity
- 2026-09-11
- Last synced
-
2026-09-16 10:16:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signal Scored 2026-09-15
NOVT presents a mixed profile: a strong balance sheet (liquidity score 85) provides a solid safety net, but deteriorating operational fundamentals (trend score 35) — marked by margin compression and poor cash conversion…
The first sentence of the analysis written for NOVT on 2026-09-15 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 41.6% | 44.4% | 45.4% | 44.0% | 42.5% | |
| Ebit Margin | 9.3% | 13.1% | 14.0% | 12.5% | 11.6% | |
| Ebitda Margin | 15.6% | 18.9% | 19.3% | 18.7% | 17.8% | |
| Operating Profit Margin | 11.9% | 11.6% | 12.5% | 12.0% | 9.1% | |
| Pretax Profit Margin | 7.1% | 8.3% | 9.5% | 10.1% | 7.9% | |
| Continuous Operations Profit Margin | 5.5% | 6.8% | 8.3% | 8.6% | 7.1% | |
| Net Profit Margin | 5.5% | 6.8% | 8.3% | 8.6% | 7.1% | |
| Bottom Line Profit Margin | 5.5% | 6.8% | 8.3% | 8.6% | 7.1% | |
| Current Ratio | 3.685 | 2.584 | 2.984 | 2.556 | 2.032 | |
| Quick Ratio | 2.799 | 1.723 | 1.911 | 1.535 | 1.349 | |
| Solvency Ratio | 0.235 | 0.186 | 0.216 | 0.192 | 0.133 | |
| Cash Ratio | 1.793 | 0.679 | 0.755 | 0.608 | 0.638 | |
| Price To Earnings Ratio | 80.946 | 85.826 | 82.961 | 65.322 | 124.176 | |
| Price To Earnings Growth Ratio | -4.648 | -6.969 | -34.512 | 1.405 | 10.514 | |
| Forward Price To Earnings Growth Ratio | -4.648 | -6.969 | -34.512 | 1.405 | 10.514 | |
| Price To Earnings Diluted Ratio | 80.946 | 86.311 | 83.371 | 65.956 | 125.057 | |
| Price To Earnings Diluted Growth Ratio | -4.776 | -6.974 | -42.936 | 1.431 | 9.770 | |
| Price To Book Ratio | 3.313 | 7.365 | 8.963 | 8.387 | 11.973 | |
| Price To Sales Ratio | 4.440 | 5.786 | 6.847 | 5.627 | 8.831 | |
| Price To Free Cash Flow Ratio | 89.899 | 38.854 | 60.296 | 68.095 | 86.149 | |
| Price To Operating Cash Flow Ratio | 67.967 | 34.648 | 50.273 | 53.361 | 65.959 | |
| Debt To Assets Ratio | 0.189 | 0.339 | 0.330 | 0.394 | 0.402 | |
| Debt To Equity Ratio | 0.260 | 0.632 | 0.601 | 0.847 | 0.946 | |
| Debt To Capital Ratio | 0.206 | 0.387 | 0.375 | 0.459 | 0.486 | |
| Long Term Debt To Capital Ratio | 0.161 | 0.356 | 0.342 | 0.427 | 0.452 | |
| Financial Leverage Ratio | 1.375 | 1.862 | 1.821 | 2.149 | 2.355 | |
| Working Capital Turnover Ratio | 2.346 | 3.503 | 3.314 | 3.862 | 3.722 | |
| Operating Cash Flow Ratio | 0.302 | 0.945 | 0.863 | 0.552 | 0.514 | |
| Operating Cash Flow Sales Ratio | 0.065 | 0.167 | 0.136 | 0.105 | 0.134 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.756 | 0.892 | 0.834 | 0.784 | 0.766 | |
| Debt Service Coverage Ratio | 1.948 | 3.522 | 4.007 | 5.108 | 5.859 | |
| Interest Coverage Ratio | 5.433 | 3.512 | 4.280 | 6.601 | 8.671 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.308 | 10.341 | 8.654 | 6.846 | 7.262 | |
| Operating Cash Flow Coverage Ratio | 0.188 | 0.337 | 0.297 | 0.185 | 0.192 | |
| Capital Expenditure Coverage Ratio | 4.099 | 9.236 | 6.015 | 4.621 | 4.267 | |
| Dividend Paid And Capex Coverage Ratio | 4.099 | 9.236 | 6.015 | 4.621 | 4.267 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 28.191 | 32.521 | 37.288 | 32.582 | 52.742 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 41.6% | ▼-2.8% | ▼-2.0% |
| Ebit Margin | 9.3% | ▼-3.8% | ▼-2.8% |
| Ebitda Margin | 15.6% | ▼-3.3% | ▼-2.4% |
| Operating Profit Margin | 11.9% | ▲0.2% | ▲0.5% |
| Pretax Profit Margin | 7.1% | ▼-1.2% | ▼-1.5% |
| Continuous Operations Profit Margin | 5.5% | ▼-1.3% | ▼-1.8% |
| Net Profit Margin | 5.5% | ▼-1.3% | ▼-1.8% |
| Bottom Line Profit Margin | 5.5% | ▼-1.3% | ▼-1.8% |
| Current Ratio | 3.685 | ▲1.101 | ▲0.917 |
| Quick Ratio | 2.799 | ▲1.076 | ▲0.935 |
| Solvency Ratio | 0.235 | ▲0.049 | ▲0.043 |
| Cash Ratio | 1.794 | ▲1.114 | ▲0.899 |
| Price To Earnings Ratio | 80.946 | ▼-4.880 | ▼-6.901 |
| Price To Earnings Growth Ratio | -4.648 | ▲2.321 | ▲2.194 |
| Forward Price To Earnings Growth Ratio | -4.648 | ▲2.321 | ▲2.194 |
| Price To Earnings Diluted Ratio | 80.946 | ▼-5.365 | ▼-7.383 |
| Price To Earnings Diluted Growth Ratio | -4.776 | ▲2.198 | ▲3.921 |
| Price To Book Ratio | 3.313 | ▼-4.052 | ▼-4.688 |
| Price To Sales Ratio | 4.440 | ▼-1.346 | ▼-1.866 |
| Price To Free Cash Flow Ratio | 89.899 | ▲51.045 | ▲21.240 |
| Price To Operating Cash Flow Ratio | 67.968 | ▲33.320 | ▲13.526 |
| Debt To Assets Ratio | 0.189 | ▼-0.150 | ▼-0.142 |
| Debt To Equity Ratio | 0.260 | ▼-0.372 | ▼-0.397 |
| Debt To Capital Ratio | 0.206 | ▼-0.181 | ▼-0.176 |
| Long Term Debt To Capital Ratio | 0.161 | ▼-0.195 | ▼-0.187 |
| Financial Leverage Ratio | 1.375 | ▼-0.487 | ▼-0.537 |
| Working Capital Turnover Ratio | 2.346 | ▼-1.157 | ▼-1.003 |
| Operating Cash Flow Ratio | 0.302 | ▼-0.643 | ▼-0.333 |
| Operating Cash Flow Sales Ratio | 0.065 | ▼-0.102 | ▼-0.056 |
| Free Cash Flow Operating Cash Flow Ratio | 0.756 | ▼-0.136 | ▼-0.050 |
| Debt Service Coverage Ratio | 1.948 | ▼-1.574 | ▼-2.141 |
| Interest Coverage Ratio | 5.433 | ▲1.921 | ▼-0.266 |
| Short Term Operating Cash Flow Coverage Ratio | 1.308 | ▼-9.033 | ▼-5.574 |
| Operating Cash Flow Coverage Ratio | 0.188 | ▼-0.149 | ▼-0.052 |
| Capital Expenditure Coverage Ratio | 4.099 | ▼-5.137 | ▼-1.549 |
| Dividend Paid And Capex Coverage Ratio | 4.099 | ▼-5.137 | ▼-1.549 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 28.191 | ▼-4.330 | ▼-8.474 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.35B | $5.49B | $6.04B | $4.84B | $6.24B | |
| Enterprise value | $4.31B | $5.85B | $6.34B | $5.23B | $6.62B | |
| EV / Sales | 4.40x | 6.16x | 7.19x | 6.08x | 9.36x | |
| EV / Op. cash flow | 67.36x | 36.90x | 52.77x | 57.65x | 69.93x | |
| EV / Free cash flow | 89.09x | 41.38x | 63.29x | 73.57x | 91.34x | |
| EV / EBITDA | 28.19x | 32.52x | 37.29x | 32.58x | 52.74x | |
| Net debt / EBITDA | -0.26x | 1.99x | 1.76x | 2.42x | 3.00x | |
| Current ratio | 3.69x | 2.58x | 2.98x | 2.56x | 2.03x | |
| Income quality | 1.19x | 2.47x | 1.65x | 1.23x | 1.88x | |
| Graham number | $34 | $29 | $29 | $28 | $22 | |
| Graham net-net | $3 | -$10 | -$7 | -$11 | -$12 | |
| Tax burden | 77.3% | 81.1% | 87.0% | 85.0% | 89.6% | |
| Interest burden | 76.4% | 63.6% | 67.9% | 81.1% | 68.4% | |
| Working capital | $570.2M | $265.9M | $276.1M | $256.0M | $189.9M | |
| Invested capital | $1.56B | $1.19B | $1.05B | $1.06B | $1.03B | |
| Return on assets | 3.0% | 4.6% | 5.9% | 6.0% | 4.1% | |
| Operating ROA | 7.3% | 8.5% | 9.0% | 8.3% | 6.1% | |
| Return on tangible assets | 5.5% | 10.4% | 12.2% | 12.6% | 9.5% | |
| Return on equity | 4.1% | 8.6% | 10.8% | 12.8% | 9.7% | |
| Return on invested capital | 5.5% | 7.3% | 8.7% | 8.0% | 5.4% | |
| Return on capital employed | 7.3% | 9.1% | 10.2% | 9.6% | 6.1% | |
| Earnings yield | 1.2% | 1.2% | 1.2% | 1.5% | 0.8% | |
| Free cash flow yield | 1.1% | 2.6% | 1.7% | 1.5% | 1.2% | |
| Capex / Op. cash flow | 24.4% | 10.8% | 16.6% | 21.6% | 23.4% | |
| Capex / Depreciation | 25.2% | 30.9% | 42.8% | 37.0% | 51.1% | |
| Capex / Sales | 1.6% | 1.8% | 2.3% | 2.3% | 3.1% | |
| SG&A / Sales | 20.0% | 18.5% | 18.7% | 18.5% | 18.3% | |
| R&D / Sales | 9.7% | 10.1% | 10.4% | 10.0% | 10.3% | |
| Stock comp / Sales | 3.0% | 2.5% | 2.9% | 2.7% | 3.6% | |
| Intangibles / Total assets | 45.8% | 55.5% | 51.3% | 52.7% | 57.0% | |
| Days sales outstanding | 69d | 58d | 58d | 58d | 60d | |
| Days payables outstanding | 60d | 53d | 43d | 57d | 62d | |
| Operating cycle | 189d | 158d | 171d | 185d | 173d | |
| Cash conversion cycle | 128d | 105d | 128d | 129d | 111d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-20.7%EV / Sales ▼-28.6%EV / EBITDA ▼-13.3%EV / Op. cash flow ▲+30.455Earnings yield ▲+0.001Graham number ▲+5.638
Profitability
Return on equity ▼-0.045Return on assets ▼-0.016Return on invested capital ▼-0.018Return on capital employed ▼-0.017Operating ROA ▼-0.012Income quality ▼-1.283Tax burden ▼-0.038
Efficiency
Days sales outstanding ▲+10.744Days payables outstanding ▲+7.267Operating cycle ▲+30.703Cash conversion cycle ▲+23.436Capex / Sales ▼-0.002R&D / Sales ▼-0.003
Balance-sheet strength
Current ratio ▲+1.101Net debt / EBITDA ▼-2.242Working capital ▲+304377000.000Invested capital ▲+366704000.000Intangibles / Total assets ▼-0.096
Change over 5 years
Valuation
Market cap ▼-30.2%EV / Sales ▼-53.0%EV / EBITDA ▼-46.5%EV / Op. cash flow ▼-2.578Earnings yield ▲+0.004Graham number ▲+12.775
Profitability
Return on equity ▼-0.056Return on assets ▼-0.011Return on invested capital ▲+0.001Return on capital employed ▲+0.012Operating ROA ▲+0.012Income quality ▼-0.690Tax burden ▼-0.123
Efficiency
Days sales outstanding ▲+9.110Days payables outstanding ▼-1.074Operating cycle ▲+16.251Cash conversion cycle ▲+17.325Capex / Sales ▼-0.015R&D / Sales ▼-0.005
Balance-sheet strength
Current ratio ▲+1.653Net debt / EBITDA ▼-3.253Working capital ▲+380347000.000Invested capital ▲+532393000.000Intangibles / Total assets ▼-0.112
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2022-07-25 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2019-10-22 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-08-01 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-05-22 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-04-17 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-04-15 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-04 Are Robots the New Normal? Bet on these ETFs to Invest in the Future Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector''s growth.
- 2026-09-01 Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Novanta Inc. $NOVT Connor Clark and Lunn Investment Management Ltd. acquired a new position in Novanta Inc. (NASDAQ: NOVT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,845 shares of the technology company''s stock, valued at approximately $786,000. Several other large investors have
- 2026-08-28 Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026 BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical a.
- 2026-08-18 Recent Price Trend in Novanta (NOVT) is Your Friend, Here''s Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 2026-08-12 Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-12 Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE Bank of America Corp DE increased its stake in Novanta Inc. (NASDAQ: NOVT) by 18.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,241 shares of the technology company''s stock after acquiring an additional 70,728 shares during the
- 2026-08-07 Amundi Purchases 3,516 Shares of Novanta Inc. $NOVT Amundi increased its position in shares of Novanta Inc. (NASDAQ: NOVT) by 17.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,187 shares of the technology company''s stock after buying an additional 3,516 shares during the quarter. Amundi owned 0.07% of
- 2026-08-07 Novanta Q2 Earnings Call Highlights Novanta (NASDAQ: NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra said reported revenue grew 10% year over year during the quarter, while adjusted EBITDA increased 16%
- 2026-08-07 Novanta Q2 Earnings Call Highlights Novanta NASDAQ: NOVT reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition.
- 2026-08-06 Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript